MX9706339A - Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. - Google Patents
Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.Info
- Publication number
- MX9706339A MX9706339A MX9706339A MX9706339A MX9706339A MX 9706339 A MX9706339 A MX 9706339A MX 9706339 A MX9706339 A MX 9706339A MX 9706339 A MX9706339 A MX 9706339A MX 9706339 A MX9706339 A MX 9706339A
- Authority
- MX
- Mexico
- Prior art keywords
- piretanide
- peak
- around
- solution
- amorphous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Glass Compositions (AREA)
Abstract
La presente invencion se refiere a la piretanida amorfa que tiene las siguientes características: (a) picos exotérmicos alrededor de 136°C y alrededor de 209°C, 8b) un pico exotérmico alrededor de 207°C y (c) un pico de fusion alrededor de 225°C en curvas térmicas diferenciales; (d) un halopatron sin pico de difraccion (20) en un análisis de difraccion por energía de rayos x, y (e) absorciones características alrededor de 1700 cm-1 y 3200-3500 cm-1 en espectro de absorcion infrarrojo, y que tiene una solubilidad alrededor de la neutralidad y una biodisponibilidad superior efectiva en la forma de administracion oral o inyeccion, la cual se prepara disolviendo piretanida en una solucion acuosa de una base, ajustando un valor de pH de la solucion mediante un ácido a un rango de pH de no menos de 3.07 y no más de 4.37 y la recuperacion de precipitado así separado, y al polimorfo de peretanida que tiene las siguientes características: (a) un pico endotérmico alrededor de 132°C, (b) un pico exotérmico alrededor de 143°C y (c) un pico de fusion alrededor de 224°C, en curvas térmicas diferenciales; (d) un halopatron sin pico de difraccion (20) a 10.5, 12.2, 15.6, 19.1, 19.9, 22.0, 22.9, 25.6 y 30.6° en un análisis de (e) absorciones características alrededor de 1700 cm1 y 3200-3500 cm1 en un espectro de absorcion infrarroja, y que tiene una solubilidad superior alrededor de la neutralidad y una biodisponibilidad superior efectiva en la forma de administracion oral o inyeccion, la cual se prepara mediante la disolucion del piretanida en una solucion acuosa de una base, ajustando un valor de pH de al solucion a un rango de pH de menos de 3.50 mediante un ácido y la recuperacion del precipitado así obtenido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03321595A JP3532987B2 (ja) | 1995-02-22 | 1995-02-22 | 新規な無晶形ピレタニドおよびその製造方法 |
| JP03321695A JP3532988B2 (ja) | 1995-02-22 | 1995-02-22 | ピレタニドの新規な結晶多形およびその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9706339A true MX9706339A (es) | 1998-07-31 |
Family
ID=26371876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9706339A MX9706339A (es) | 1995-02-22 | 1997-08-20 | Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6096779A (es) |
| EP (1) | EP0812320B1 (es) |
| KR (1) | KR100419355B1 (es) |
| CN (1) | CN1072215C (es) |
| AT (1) | ATE194607T1 (es) |
| BR (1) | BR9607295A (es) |
| CA (1) | CA2213693C (es) |
| DE (1) | DE69609314T2 (es) |
| DK (1) | DK0812320T3 (es) |
| ES (1) | ES2150105T3 (es) |
| GR (1) | GR3034605T3 (es) |
| HK (1) | HK1006783A1 (es) |
| MX (1) | MX9706339A (es) |
| PT (1) | PT812320E (es) |
| WO (1) | WO1996026197A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW526195B (en) | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
| DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
| HRP20000162B1 (en) | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
| NZ536497A (en) * | 2002-05-16 | 2006-08-31 | Tibotec Pharm Ltd | Pseudopolymorphic forms of a HIV protease inhibitor and their use as a medicament |
| EP1734931A2 (en) * | 2004-03-24 | 2006-12-27 | Actavis Group | Formulations of ramipril |
| GB2431579A (en) * | 2005-10-28 | 2007-05-02 | Arrow Int Ltd | Ramipril formulations |
| US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2419970C3 (de) * | 1974-04-25 | 1980-06-12 | Hoechst Ag, 6000 Frankfurt | 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung |
| JPS5283547A (en) * | 1976-01-01 | 1977-07-12 | Hoechst Ag | Tertiary cyclic amine |
| DE2655331A1 (de) * | 1976-12-07 | 1978-06-08 | Hoechst Ag | Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung |
| ES2025085B3 (es) * | 1986-04-29 | 1992-03-16 | Hoechst-Roussel Pharmaceuticals Incorporated | Una estructura laminar para la administracion de un producto quimico a una velocidad de liberacion controlada. |
| EP0465841A3 (en) * | 1990-06-13 | 1992-10-14 | Hoechst Aktiengesellschaft | Quick acting pharmaceutical inhalation forms of diuretics |
| JPH05230044A (ja) * | 1992-02-21 | 1993-09-07 | Hoechst Japan Ltd | ピレタニドの新規な結晶多形 |
-
1996
- 1996-02-12 DK DK96904993T patent/DK0812320T3/da active
- 1996-02-12 EP EP96904993A patent/EP0812320B1/en not_active Expired - Lifetime
- 1996-02-12 PT PT96904993T patent/PT812320E/pt unknown
- 1996-02-12 US US08/894,412 patent/US6096779A/en not_active Expired - Lifetime
- 1996-02-12 BR BR9607295A patent/BR9607295A/pt not_active IP Right Cessation
- 1996-02-12 KR KR1019970705772A patent/KR100419355B1/ko not_active IP Right Cessation
- 1996-02-12 ES ES96904993T patent/ES2150105T3/es not_active Expired - Lifetime
- 1996-02-12 WO PCT/IB1996/000254 patent/WO1996026197A1/en active IP Right Grant
- 1996-02-12 DE DE69609314T patent/DE69609314T2/de not_active Expired - Lifetime
- 1996-02-12 AT AT96904993T patent/ATE194607T1/de active
- 1996-02-12 CN CN96192081A patent/CN1072215C/zh not_active Expired - Lifetime
- 1996-02-12 CA CA002213693A patent/CA2213693C/en not_active Expired - Lifetime
-
1997
- 1997-08-20 MX MX9706339A patent/MX9706339A/es unknown
-
1998
- 1998-06-18 HK HK98105624A patent/HK1006783A1/xx not_active IP Right Cessation
-
2000
- 2000-10-12 GR GR20000402289T patent/GR3034605T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69609314T2 (de) | 2001-06-13 |
| GR3034605T3 (en) | 2001-01-31 |
| KR100419355B1 (ko) | 2004-06-04 |
| KR19980702374A (ko) | 1998-07-15 |
| CN1175948A (zh) | 1998-03-11 |
| DE69609314D1 (de) | 2000-08-17 |
| CA2213693A1 (en) | 1996-08-29 |
| BR9607295A (pt) | 1997-11-25 |
| EP0812320A1 (en) | 1997-12-17 |
| DK0812320T3 (da) | 2003-04-14 |
| ES2150105T3 (es) | 2000-11-16 |
| PT812320E (pt) | 2000-12-29 |
| CN1072215C (zh) | 2001-10-03 |
| WO1996026197A1 (en) | 1996-08-29 |
| EP0812320B1 (en) | 2000-07-12 |
| ATE194607T1 (de) | 2000-07-15 |
| CA2213693C (en) | 2008-04-15 |
| US6096779A (en) | 2000-08-01 |
| HK1006783A1 (en) | 1999-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4294828A (en) | New derivatives of 4-amino-5-alkyl sulphonyl orthoanisamides, methods of preparing them and their application as psychotropic agents | |
| US20090203630A1 (en) | Process for preparing atazanavir bisulfate and novel forms | |
| HUT59109A (en) | Process for producing hydroxymethyl-(methylenecyclopentyl)-purines and -pyrimidines, their pharmaceutically acceptable salts and pharmaceutical compositions comprising same | |
| MX9706339A (es) | Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. | |
| HUT52480A (en) | Process for producing 3,5-dimethyl-4-methoxypyridine derivatives | |
| AU2606592A (en) | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs, a process for their preparation and their use as medicaments | |
| GB2045756A (en) | Hydroxy derivatives of 2- isopropylamino-pyrimidine | |
| AU534470B2 (en) | Paromomycin derivatives | |
| AU4442389A (en) | 1,2,3,4-tetrahydro-1,9-acridinediamines, a process for their preparation and their use as medicaments | |
| ES2070018T3 (es) | Procedimiento para la preparacion de 2-cloro-5-clorometil-piridina. | |
| CA2614979A1 (en) | Piretanide polymorph, process for its preparation and its use | |
| AU636178B2 (en) | 7 (alanylaminothiazol-iminoacetamide) substituted cephalosporin derivatives | |
| JPS6116272B2 (es) | ||
| EP1207156A4 (en) | SUBSTITUTED BENZYLTHIAZOLIDINE-2,4-DION DERIVATIVES | |
| EP1285917A4 (en) | PROCESS FOR THE PREPARATION OF CARBOSTYRIL DERIVATIVES | |
| CA2308067A1 (en) | Novel crystals of depsipeptide derivative and a method for producing the same | |
| EP0011854B1 (en) | 4-(2'-pyridylamino)-phenylacetic acid derivatives, process for their preparation, pharmaceuticals containing these compounds and their use | |
| HUT45012A (en) | Process for producing substituted indolinone derivatives | |
| ES8708213A1 (es) | Un procedimiento para preparar un derivado de 1-benzhidril--4-cinamilpiperazina | |
| Sadeh et al. | The preparation of selenium‐containing aromatic and heterocyclic C‐substituted α‐amino acetic acid derivatives of potential biomedical application | |
| US4415578A (en) | Cardiotonic 3-methyl-4-(4-pyridinyl)benzeneamine compositions and method of use | |
| JPS60248688A (ja) | 新規のアポビンカミン酸エステルおよびその酸付加塩並びにその製造方法 | |
| HUT58292A (en) | Process for producing acid additional salts of an optically active alanine-anilide derivative and pharmaceutical compositions containing them | |
| GB1579270A (en) | 1-methyl-2-substituted-methyl-k-nitroimidazoles | |
| GB2061920A (en) | Aluminum co-precipitate of sucrose sulfate dihydroxyaluminium allantoinate |